• First-in-human Phase 1 study initiated for investigational antibodies targeting orthopoxviruses developed under U.S. Department of War Accelerated Antibodies Program
  • Supports development of countermeasures against orthopoxviruses, a high-priority biological threat family that includes viruses responsible for smallpox
  • Delivers integrated process development, regulatory submission and manufacturing of clinical trial material at J.POD® Redmond facility
  • Demonstrates scalable model for development and continuous manufacturing for biodefense preparedness